Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Kiniksa Pharmaceuticals International operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Kiniksa Pharmaceuticals International's operating cash flow for the twelve months ending Sep 30, 2026 was $198.84M, up 93.3% year over year. For fiscal 2025 it was $137.99M, up 437.1% from the year before. The highest annual figure on record is $137.99M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.99M | +437.1% |
| FY2024 | Dec 31, 2024 | $25.69M | +93.1% |
| FY2023 | Dec 31, 2023 | $13.30M | +129.1% |
| FY2022 | Dec 31, 2022 | $5.81M | – |
| FY2021 | Dec 31, 2021 | -$126.30M | – |
| FY2020 | Dec 31, 2020 | -$136.53M | – |
| FY2019 | Dec 31, 2019 | -$158.37M | – |
| FY2018 | Dec 31, 2018 | -$81.01M | – |
| FY2017 | Dec 31, 2017 | -$50.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $47.55M | +41.2% |
| Q2 FY2026 | Jun 30, 2026 | $47.20M | +68.0% |
| Q1 FY2026 | Mar 31, 2026 | $50.20M | +124.9% |
| Q4 FY2025 | Dec 31, 2025 | $53.89M | +187.1% |
| Q3 FY2025 | Sep 30, 2025 | $33.68M | – |
| Q2 FY2025 | Jun 30, 2025 | $28.09M | +443.5% |
| Q1 FY2025 | Mar 31, 2025 | $22.32M | +459.9% |
| Q4 FY2024 | Dec 31, 2024 | $18.77M | +334.0% |
| Q3 FY2024 | Sep 30, 2024 | -$2.24M | -113.2% |
| Q2 FY2024 | Jun 30, 2024 | $5.17M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.99M | – |
| Q4 FY2023 | Dec 31, 2023 | $4.33M | – |
| Q3 FY2023 | Sep 30, 2023 | $16.99M | -72.6% |
| Q2 FY2023 | Jun 30, 2023 | -$3.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.58M | – |
| Q3 FY2022 | Sep 30, 2022 | $62.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$36.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$38.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$40.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$41.19M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$29.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$31.80M | – |
| Q4 FY2019 | Dec 31, 2019 | -$24.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$63.26M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.64M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.92M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.97M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.94M | – |
See a number that looks wrong?